Skip to content
Archive

KOLINPHARMA® expands its product portfolio with the launch of Kymax®

In recent decades world demographics have changed considerably, with a progressive ageing of the global population that will continue thanks to the constant advances of medicine. Ageing is the main risk factor for chronic diseases, including neurodegenerative diseases.

Kymax®, the second product in the line dedicated to neuroscience, thanks to its specifically selected active compounds, and in particular the B-group vitamins, aims to support the proper functioning of the nervous system.

This launch is another significant step in Kolinpharma’s growth strategy in the nutraceutical sector, underlining the company’s commitment to providing innovative health solutions and highlighting the effectiveness and importance of its in-house research and development department.

Kymax®, thanks to its specifically selected active compounds, can help to support normal mood, thanks to its saffron dry extract, and brain function, thanks to DHA Origins®, the balance of the intestinal flora, with L.rhamnosus LR-06 and inulin, and to act on physical and mental tiredness, with green tea dry extract.

Read the article on Index Medical

More news

  1. KOLINPHARMA®: Credit Reputation Award received
  2. KOLINPHARMA®: NEW PATENT IN CHINA FOR DOLTENDIX®
  3. Kolinpharma® is pleased to announce the launch of KIPFeR®
Archive